Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1625 1674
This examiner grants 73% of resolved cases
Nizal S Chandrakumar is an examiner in Tech Center 1600 and Art Unit 1625. The examiner has a high volume of 1785 resolved cases and an allowance rate of 72.7%. This 72.7% rate indicates a favorable environment for applicants, with nearly three-quarters of cases reaching allowance. The 1785 resolved cases provide an exceptionally reliable statistical foundation for this trend.
The interview lift is 18.3%, suggesting that personal engagement with the examiner is a beneficial strategy. This 18.3% lift can help resolve outstanding issues and move a case toward a grant. The median days to allowance is 833, which is a relatively short timeframe for patent prosecution. Practitioners should expect an 833-day process and use the 18.3% lift to maintain momentum. The combination of a 72.7% allowance rate and an 833-day median suggests that this examiner is efficient at moving cases to a successful conclusion. The 1785 resolved cases show a consistent pattern of timely and favorable outcomes.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17836814 | ORAL PRODUCTS WITH REDUCED IRRITATION | Final Rejection | NICOVENTURES TRADING LIMITED |
| 17794003 | MECHANOCHEMICAL SNAr REACTIONS | Non-Final OA | nChain Licensing AG |
| 18111350 | RESPONSE-GUIDED HCV THERAPY | Non-Final OA | Emory University |
| 18859007 | LIPIDS, FORMULATIONS, AND USES THEREOF | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18555301 | METHOD FOR PREPARING LACTONES HAVING AT LEAST ONE GROUP SELECTED FROM CARBOXYL, CARBOALKOXY, HYDROXY AND CARBOXYLATE | Final Rejection | BASF SE |
| 18705232 | PESTICIDALLY ACTIVE PYRIDAZINONE COMPOUNDS | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18853224 | IMMUNE MODULATORY AGENTS | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18633298 | Metal-Assisted Delayed Fluorescent Emitters Employing Benzo-imidazo-phenanthridine and Analogues | Final Rejection | Arizona Board of Regents on behalf of Arizona State University |
| 18035280 | CAR T CELL THERAPY IN PATIENTS WHO HAVE HAD PRIOR ANTI-CANCER ALKYLATOR THERAPY | Final Rejection | Juno Therapeutics, Inc. |
| 18856717 | NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE AND N-PROPYL-AZETIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Non-Final OA | SANOFI |
| 18548635 | HETEROBIFUNCTIONAL COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION AND METHODS FOR THEIR USE | Final Rejection | THE SCRIPPS RESEARCH INSTITUTE |
| 18562107 | SOTORASIB DOSING REGIMEN | Non-Final OA | AMGEN INC. |
| 18549852 | METHODS FOR TREATING SMALL CELL LUNG CANCER AND OTHER NEUROENDOCRINE CANCERS | Non-Final OA | AstraZeneca AB |
| 18569361 | ROS-RESPONSIVE CAPTOPRIL-CINNAMALDEHYDE PRODRUGS AND COMPOSITIONS AND METHODS THEREOF | Non-Final OA | The University of Hong Kong |
| 18671477 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | Non-Final OA | Incyte Corporation |
| 17800049 | HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS | Non-Final OA | Givaudan SA |
| 18285264 | ASPARTIC ACID COPPER COMPLEX, AND USE THEREOF | Final Rejection | GUANGZHOU INSIGHTER BIOTECHNOLOGY CO., LTD. |
| 17781467 | COMPOSITIONS AND METHODS RELATED TO MOLECULAR CONJUGATION | Final Rejection | IntoCell, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy